Mirum Pharmaceuticals Q1 Earnings Focus on Livmarli Sales Growth

Mirum Pharmaceuticals is approaching its first-quarter earnings report with significant attention on the performance of Livmarli, a bile acid product. In 2025, Livmarli achieved a 69% increase in sales compared to the previous year. This growth has contributed to expanding revenue streams for the company. The upcoming financial results will reveal whether this upward trend continues into the new quarter. Bile acid therapies are playing a key role in driving Mirum's financial momentum. Investors are closely monitoring these developments as they assess the company's market position. The earnings report will provide insights into the product's impact on overall financial health. No specific dates or locations are mentioned in the source material.